This website uses cookies to give you the best, most relevant experience. Using the website means you are Ok with this.



Peter ObrienProf. Peter O’Brien joined the University of York in 1996 and was promoted to Professor in 2007. He is the recipient of the RSC Organic Stereochemistry Prize (2013 – for development and applications of the (+)-sparteine surrogate), a GlaxoWellcome Award (2000) and the RSC Meldola Medal (1999). He has published 125 papers and has a h-index of 32. In research since 2010, the O’Brien group have reported the first high yielding asymmetric lithiation-trapping of N-Boc piperidine, synthetic reactions showing that (+)-sparteine surrogate complexed to i-PrLi or s-BuLi in THF whereas (–)-sparteine did not (with Hilmersson), synthesis of 3-D lead-like scaffolds using N-Boc α-lithiation (with Hubbard) and the preparation of enantiomerically pure Grignard reagents. Recently, O’Brien has pioneered the use of in situ React IR spectroscopy to monitor the lithation of N-Boc heterocycles, work carried out via collaborations with Merck (USA), AstraZeneca and Lilly including the first example of real-time monitoring of N-Boc rotamer interconversion using in situ React IR (with Coldham). Currently, the group has two research themes: (i) discovery of new asymmetric α-lithiation methodology and application in medicinal chemistry; (ii) design, synthesis and evaluation of 3-D fragments for the systematic exploration of 3-D pharmaceutical space – a project supported by a pharmaceutical consortium (Astex, AstraZeneca, Lilly, Pfizer and Vernalis).


Website link: 





Contact details

Please contact us at:

FRAGNET Coordinator
VU University Amsterdam
The Netherlands

Funded by

marie curie actions   Marie Curie Actions



EU Horizon 2020



european union logo   European Union